Navigation Links
Former Senator Byron Dorgan Elected to Codexis Board
Date:2/17/2011

REDWOOD CITY, Calif., Feb. 17, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that Byron Dorgan, former U.S. Senator from North Dakota, has been elected to the company's Board of Directors. Senator Dorgan retired from the Senate in January 2011 after a 30-year career in the U.S. Congress.  

(Photo:  http://photos.prnewswire.com/prnh/20110217/SF50619)

"We are very pleased to welcome Byron Dorgan to our Board," said Alan Shaw, Ph.D., President and Chief Executive Officer.  "He is a champion of new technologies to enable innovation and has long advocated energy security through a comprehensive national energy policy. As Chairman of the Senate Energy and Water Appropriations Subcommittee, he worked to fund broad development of renewable energy sources. His substantial expertise will be valuable to Codexis."

Senator Dorgan served in the Senate leadership for 16 years, first as Assistant Democratic Floor Leader and then as Chairman of the Democratic Policy Committee. He was Chairman of the Senate Committees and Subcommittees on the issues of Appropriations, Commerce, Energy, Aviation, Water Policy, and Indian Affairs. First elected to Congress in 1980, Dorgan served six terms in the U.S. House of Representatives and three terms in the U.S. Senate. He was also North Dakota's youngest-ever constitutional officer when he was appointed State Tax Commissioner.

While in Congress, he built a reputation as a forward-looking energy policy maker, supporting the use of renewable energy and domestic energy sources, and moving away from a reliance on foreign oil.  He also emerged as one of the nation's leading voices on behalf of America's agriculture industry. He worked to expand North Dakota's burgeoning energy sector, preserve a strong safety net for family farmers, and spur economic development.

Senator Dorgan earned his Bachelor of Science degree from the University of North Dakota and his Master of Business Administration from the University of Denver.

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell and carbon capture with Alstom. Other potential markets for the company's biocatalyst-enabled solutions include chemicals and water treatment. For more information, see www.codexis.com.

Contact: Media; Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.  Investors; Robert Lawson, robert.lawson@codexis.com, 650-421-8137


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Former Speaker of the House Newt Gingrich Featured Wednesday
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Former Cables to Go/Lastar Inc. Employee's Move to Form American Consumer Cables Pays Off
4. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
5. Former Telomolecular CEO Clarifies SEC Settlement
6. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
7. Former NASDAQ International President Among Execs Launching Firm to Access Global Markets
8. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
9. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
10. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
11. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 18, 2017 , ... The ... (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, ... subject to the existing policy. AMIA recommended that NIH earmark funding for researchers ...
(Date:1/19/2017)... 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), ... for operable and inoperable solid tumor cancers, announced today ... of NW Bio, will present at the Phacilitate Immunotherapy ... Hyatt Regency Hotel in Miami, Florida ... entitled "New Therapeutic Approaches – Expanding the Reach of ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017   Boston ... novel compounds designed to target cancer stemness pathways, will ... investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers ... Francisco . Napabucasin is an ... by targeting STAT3. i Cancer stem cells (CSCs) ...
(Date:1/18/2017)... ... January 18, 2017 , ... Whitehouse Labs has furthered ... Molecular Research, Inc. (AMRI), the scientific staff dedicated to Extractables / Leachables & ... further growth in 2017. Extractable & Leachable evaluations have become increasingly more vital ...
Breaking Biology Technology:
(Date:1/11/2017)... 2017  Michael Johnson, co-founder of Visikol Inc. a company originally ... been named to the elite "Forbes 30 Under 30" list in ... people in 20 fields nationwide to be recognized as a leader ... were selected. ... is currently a PhD candidate at Rutgers University. ...
(Date:1/4/2017)... Jan. 4, 2017  For the thousands of attendees at this year,s ... in connected health and biometric measurement devices and services, will be featuring ... On display in A&D Medical,s special CES Exhibit Suite , the ... expansion of the company,s WellnessConnected product platform.  ... ...
(Date:12/22/2016)... 2016 SuperCom (NASDAQ:   ... the e-Government, Public Safety, HealthCare, and Finance sectors announced today that ... selected to implement and deploy a community-based supportive services program to ... , further expanding its presence in the state. ... This new program, which is ...
Breaking Biology News(10 mins):